规划帕金森病预防:现在是时候了
帕金森病(PD)是全球患病率不断上升的慢性进行性神经退行性疾病,目前尚无疾病修饰疗法。近几十年研究已识别出帕金森病风险显著增高的人群,本文借鉴阿尔茨海默病和亨廷顿病早期预防试验经验,聚焦帕金森病预防试验的关键设计要素,包括入组人群、待测疗法和结局测量。
要点
- 帕金森病患病率全球上升,目前尚无疾病修饰疗法。
- 已识别出帕金森病风险显著增高的人群,为预防试验提供基础。
- 预防试验设计需明确入组人群、待测疗法和结局测量。
核心结论
- 基于已识别出的帕金森病风险显著增高人群,现在应设计和实施帕金森病预防试验。
研究设计与样本
- 本文为综述,借鉴阿尔茨海默病和亨廷顿病早期预防试验经验,聚焦帕金森病预防试验的关键设计要素。
主要发现
- 帕金森病是慢性进行性神经退行性疾病,全球患病率不断上升。
- 尽管在显性帕金森病中开展了许多神经保护疗法试验,但尚无疾病修饰疗法被确立。
- 近几十年一系列突破已识别出帕金森病风险显著增高的离散人群。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Parkinson disease (PD) is a chronic progressive neurodegenerative disease with increasing worldwide prevalence. Despite many trials of neuroprotective therapies in manifest PD, no disease-modifying therapy has been established. Over the past several decades, a series of breakthroughs have identified discrete populations at substantially increased risk of developing PD. Based on this knowledge, now is the time to design and implement PD prevention trials. This endeavor builds on experience gained from early prevention trials in Alzheimer disease and Huntington disease. This article first reviews prevention trial precedents in these other neurodegenerative diseases before focusing on the critical design elements for PD prevention trials, including whom to enroll for these trials, what therapeutics to test, and how to measure outcomes in prevention trials. Our perspective reflects progress and remaining challenges that motivated a 2021 conference, "Planning for Prevention of Parkinson: A Trial Design Symposium and Workshop."
引用
- Crotty GF, Keavney JL, Alcalay RN, et al. Planning for Prevention of Parkinson Disease: Now Is the Time. Neurology. 2022. PMID: 36219787. doi:10.1212/WNL.0000000000200789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。